Skip to content

Study is first to link multiple myeloma protein to extramedullary disease.

Multiple myeloma, also known as myeloma, is a type of bone marrow cancer.  Multiple myeloma affects the plasma cells, blood cell, inside the bone marrow.  Myeloma does not take the form of a lump or tumour, with the myeloma cells dividing and expanding within the bone marrow, damaging bones and affecting the production of healthy blood cells.  Approximately 25% of patients with multiple myeloma also simultaneously develop extramedullary disease (EMD). This disease occurs when the myeloma cells form tumours outside of the bone marrow in the soft tissues or organs of the body. The prognosis of myeloma patients with EMD behaves like other metastatic cancers and is extremely poor because its clinical course is very aggressive.  It is known that multiple myeloma with EMD involvement has an extremely poor outcome, however, not much is known about the mechanism in which EMD progresses.  Now, a study from researchers led by the University of Louisville links AF1q, a multiple myeloma protein, with EMD.  The group presented their findings at the European Hematology Association’s 21st Congress.

Previous studies show that EMD is an uncommon manifestation in multiple myeloma and can either accompany newly diagnosed disease or develop with disease progression or relapse.  EMD is a poor prognostic marker in both newly diagnosed and relapsed myeloma patients and, therefore, is a therapeutic challenge even with the use of novel agents.  A better understanding of how myeloma cells grow and thrive, as well as the biology of extramedullary tumours, is needed in order to develop better strategies for the treatment of EMD. Research has shown that myeloma patients with EMD have a poorer prognosis than those without.  Therefore, the researchers looked at the oncogene, AF1q, which is expressed in hematological cancer cells and is known to be related to multiple myeloma. Most importantly, its presence, like EMD, indicates a poor prognosis for the patient.  The current study investigates whether the high expression of AF1q is a poor prognostic factor of multiple myeloma and associated with EMD.

The current study investigates newly diagnosed multiple myeloma patients in National Center for Global Health and Medicine hospital from January 2001 to March 2013.  The degree of expression of AF1q in 117 patients with multiple myeloma was analysed using the immuno-staining of bone marrow clot samples.  Results show that EMD was present in 25% of patients with a low AF1q expression and in 44.7% of patients with a high AF1q expression.

The lab state that, to their knowledge, this is the first study to demonstrate a molecular marker associated with myeloma with EMD.  They go on to conclude that the high expression of AF1q is an adverse prognostic factor in multiple myeloma.

The team surmise that their findings show the incidence of EMD is significantly higher in patients with high expression of AF1q than those with low expression.  For the future, the researchers state that the significance of this finding gives the medical community a tentative approach to target this marker and could lead to new therapies for this subtype of myeloma.

Source: University of Louisville

 

Multiple Myeloma.  Credit: Merck and the Merck Manuals.
Multiple Myeloma. Credit: Merck and the Merck Manuals.

Healthinnovations View All

Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.

Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.

Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.

Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.

Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.

An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.

Leave a Reply

Translate »